We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Novel Reliable Assay for Tuberculosis and LTBI Tested

By LabMedica International staff writers
Posted on 12 Feb 2020
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB) complex organisms, is still one of the most prevalent human infections worldwide estimated in 2018 with 1.2 million deaths among human immunodeficiency virus (HIV)-negative people and an additional 251,000 deaths from TB among HIV-positive people.

Additionally, 1.7 billion people in the world’s population harbor a latent tuberculosis infection (LTBI) and thus they are at risk of developing active TB disease during their lifetime Consequently, urgent action is required to improve the diagnosis of both active TB and latent infection in order to set-up new screening tests for MTB that can be used for public health to detect and treat individuals who are at high risk of developing active TB.

Clinical scientists at the University of Florence (Florence; Italy) and their colleagues consecutively enrolled a total of 250 subjects that included 151 healthy subjects, 66 active TB patients and 33 subjects with LTBI. More...
Diagnosis of active TB cases relied on clinical, microbiological and radiological findings. A group of 139 blood donors was recruited in Blood Center, Almaty, Kazakhstan; they were designated as “conditionally healthy” since all were negative by annual fluorographic examination.

The blood of all the patients was tested with LIOFeron TB/LTBI assay (Lionex GmbH (Braunschweig, Germany), containing MTB alanine dehydrogenase, able to differentiate active TB from LTBI diagnosis. This assay is an interferon-gamma release assay (IGRA) and the optical density (OD) was quantified at 450 nm with a spectrophotometer (Multiskan Go, Thermo Scientific, Waltham, MA, USA). For comparison the assay was compared with the QuantiFERON-TB Gold Plus assay (Qiagen, Hilden, Germany).

The investigators reported that the two assays demonstrated an excellent concordance of their results with patients’ diagnosis of MTB infection. Receiving Operating Characteristic (ROC) analysis for QuantiFERON-TB Gold Plus showed sensitivity and specificity respectively of 98% and 97% in diagnosing active TB patients and 85% and 94% in diagnosing LTBI subjects. LIOFeron TB/LTBI assay showed sensitivity and specificity respectively of 90% and 98% in diagnosing active TB patients and 94% and 97% in diagnosing LTBI subjects.

The authors concluded that the LIOFeron TB/LTBI assay displayed the same high accuracy as the QuantiFERON-TB Gold Plus test in diagnosing MTB infection/TB disease, and demonstrated higher sensitivity than QuantiFERON-TB Gold Plus test in LTBI detection. The study was published in the February, 2020 issue of the International Journal of Infectious Diseases.

Related Links:
University of Florence
Lionex GmbH
Thermo Scientific
Qiagen



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.